Eli Lilly & Company is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.
Eli Lilly & Co. is a pharmaceutical company that researches and treats diabetes, cancer, depression, heart disease, and other illnesses. It is known for being the first company to commercialize insulin, which treats diabetes, and for Prozac, which treats depression.
(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)
Eli Lilly & Co. has earned a spot in our top 100 for its considerable positive value associated with Healthcare R&D ($326.0 B), Pharmaceuticals ($64.8 B), and Economic Value ($6.4 B). Healthcare is important to Humankind Value, as a large contribution to modern life expectancies has come from the last 150 years of medical innovation. The company produces economic value by offering to consumers goods and services that they value, paying employees for their labor in producing these goods and services, and providing value for shareholders. Of the companies we analyzed, Lilly is in the top ten for the Healthcare R&D category. Lilly’s positive value in Healthcare R&D and Pharmaceuticals is linked to an estimated 8,109,159.0 additional life years for people worldwide. However, there is room for improvement with respect to Greenhouse Gases (-$1.3 B) and Air Pollution (-$265.2 M). We attribute Lilly’s impact on all these categories to the company’s direct business activities.